The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.
Dale Randall Shepard
Research Funding - Pfizer
Justine Yang Bruce
No relevant relationships to disclose
Ignacio Garrido-Laguna
No relevant relationships to disclose
Brad Rosbrook
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jean-Francois Martini
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Yazdi K. Pithavala
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Olga Valota
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
M Dror Michaelson
Consultant or Advisory Role - Abbott Laboratories; AVEO; Genentech; Novartis; Pfizer
Research Funding - Abbott Laboratories; Bayer; Eisai; Genentech; GlaxoSmithKline; Novartis; Pfizer